R E Beitman

  • Citations Per Year
Learn More
Acute, subacute and chronic toxicity-carcinogenicity studies of 2-[1-(2,6-dichlorphenoxy)-ethyl]-2-imidazoline hydrochloride (lofexidine, Lofetensin and Loxacor) were conducted in rats, dogs, and/or mice. The oral LD50 values for these species were similar. Lofexidine given orally to rats and dogs for up to 12 months produced no significant adverse effects(More)
alpha-[4-(1,1-Dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-1- piperidinebutanol (terfenadine, RMI 9918, Triludan, Teldane, resp.) is a new histamine H1-receptor antagonist. In clinical trials, terfenadine has been studied extensively in adult patients and to a limited extent in children. Based on the results of the double-blind placebo controlled(More)
2-[1-(2,6-Dichlorphenoxy)-ethyl]-2-imidazoline hydrochloride (lofexidine, Lofetensin and Loxacor) elicited no evidence of teratogenicity when administered orally during the period of organogenesis to pregnant rats at doses up to 3.0 mg/kg/day or to pregnant rabbits at doses up to 15.0 mg/kg/day. In reproductive studies there were no effects on conception or(More)
  • 1